North America Hemostats Market

September 2017 | 150 pages | ID: N8587C869CBEN
Data Bridge Market Research

Abstracts

In this region, North America hemostats market is projected to reach USD 2,608.4 million by 2024, from USD 1,575.2 million in 2016 growing at a CAGR of 6.5% in the forecast period 2017 to 2024.

Based on geography, the North America hemostats market is segmented into 3 geographical regions, such as,

• U.S.,
• Mexico,
• Canada

North America hemostats market competition by top players including

• Ethicon US LLC (U.S.) is dominating the hemostats market followed by Pfizer and C.R. Bard Inc., along with others such as
• Baxter,
• Vascular Solutions, Inc.,
• B.Braun Melsungen,
• 3-D Matrix, Ltd.,
• Resorba Medical GmbH (an Advanced Medical Solutions Group plc Company),
• Anika Therapeutics, Inc.,
• Arch Therapeutics Inc.,
• Biom’Up SAS,
• CryoLife, Inc.,
• Gamma Therapeutics, Inc.,
• Hemostasis, LLC,
• MedTrade Products Limited, I
• Integra LifeSciences Corporation,
• Medline Industries, Inc.,
• HEMOTEC MEDICAL GMBH,
• Stryker,
• CSL Behring,
• Mallinckrodt,
• Equimedical, B.V.

The North America hemostats market is segmented on the basis of type, application, distribution channel, and end user.

The North America hemostats market is segmented into 5 major types, namely thrombin based hemostats, combination agents, oxidized regenerated cellulose based haemostats, gelatin based haemostats and collagen based haemostats.

On the basis of application, the market is segmented into surgery and wound closure.

On the basis of end users, the market is classified into hospitals, community healthcare, ambulatory centres and clinics.

Contents

1. INTRODUCTION

1.1. OBJECTIVES OF THE STUDY
1.2. MARKET DEFINITION
1.3. OVERVIEW OF NORTH AMERICA HEMOSTATS MARKET
1.4. CURRENCY AND PRICING
1.5. LIMITATION
1.6. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCE
2.8. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS
  3.1.1. CHRONIC CONDITIONS AND AGING POPULATION LEADING TO INCREASE IN NUMBER OF SURGICAL PROCEDURES
  3.1.2. TECHNOLOGICAL ADVANCEMENTS
  3.1.3. INCREASING NUMBER OF MINIMALLY INVASIVE SURGERIES
  3.1.4. IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING HEALTHCARE SPENDING
3.2. RESTRAINTS
  3.2.1. RELUCTANCE OF SURGEONS TOWARDS NEW PRODUCTS
  3.2.2. WEAK REIMBURSEMENT
3.3. OPPORTUNITIES
  3.3.1. UNMET MEDICAL NEEDS
  3.3.2. EMERGING MARKET
3.4. CHALLENGES
  3.4.1. DEVELOPMENT OF SUBSTITUTE PRODUCTS
  3.4.2. LIMITATIONS OF HEMOSTATIC AGENTS IN ACHIEVING HEMOSTASIS

4. PREMIUM INSIGHTS

5. REGULATORY

5.1. OVERVIEW
5.2. REGULATORY PROCEDURE

6. REIMBURSEMENT

6.1. OVERVIEW
6.2. REIMBURSEMENT SCENARIO

7. EXECUTIVE SUMMARY

8. NORTH AMERICA HEMOSTATS MARKET, BY TYPE

8.1. OVERVIEW
8.2. THROMBIN BASED HEMOSTATS
8.3. COMBINATION AGENT HEMOSTATS
8.4. OXIDIZED REGENERATED CELLULOSE BASED HEMOSTATS
8.5. GELATIN BASED HEMOSTATS
8.6. COLLAGEN BASED HEMOSTATS

9. NORTH AMERICA HEMOSTATS MARKET,BY APPLICATION

9.1. OVERVIEW
9.2. NORTH AMERICA HEMOSTATS MARKET, BY APPLICATION
9.3. WOUND CLOSURE
9.4. SURGICAL HEMOSTATS

10. NORTH AMERICA HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL

10.1. OVERVIEW
  10.1.1. DIRECT TENDERS
  10.1.2. RETAIL

11. NORTH AMERICA HEMOSTATS MARKET, BY END USER

11.1. OVERVIEW
11.2. HOSPITALS
11.3. AMBULATORY CENTERS
11.4. COMMUNITY HEALTHCARE
11.5. CLINICS

12. NORTH AMERICA HEMOSTATS MARKET, BY GEOGRAPHY

12.1. OVERVIEW
12.2. NORTH AMERICA
  12.2.1. U.S.
  12.2.2. CANADA
  12.2.3. MEXICO

13. NORTH AMERICA HEMOSTATS MARKET, COMPANY LANDSCAPE

13.1. COMPANY SHARE ANALYSIS: NORTH AMERICA
13.2. COMPANY SHARE ANALYSIS: NORTH AMERICA
13.3. COMPANY SHARE ANALYSIS: EUROPE
13.4. COMPANY SHARE ANALYSIS: APAC

14. COMPANY PROFILES

14.1. ETHICON US, LLC (SUBSIDIARY OF JOHNSON &
JOHNSON SERVICES, INC)
  14.1.1. COMPANY OVERVIEW
  14.1.2. REVENUE ANALYSIS
  14.1.3. PRODUCT PORTFOLIO
  14.1.4. RECENT DEVELOPMENTS
14.2. PFIZER
  14.2.1. COMPANY OVERVIEW
  14.2.2. REVENUE ANALYSIS
  14.2.3. PRODUCT PORTFOLIO
  14.2.4. RECENT DEVELOPMENTS
14.3. C.R BARD
  14.3.1. COMPANY OVERVIEW
  14.3.2. REVENUE ANALYSIS
  14.3.3. PRODUCT PORTFOLIO
  14.3.4. RECENT DEVELOPMENTS
14.4. BAXTER
  14.4.1. COMPANY OVERVIEW
  14.4.2. REVENUE ANALYSIS
  14.4.3. PRODUCT PORTFOLIO
  14.4.4. RECENT DEVELOPMENTS
14.5. VASCULAR SOLUTIONS, INC
(ACQUIRED BY TELEFLEX INCORPORATED)
  14.5.1. COMPANY OVERVIEW
  14.5.2. REVENUE ANALYSIS
  14.5.3. PRODUCT PORTFOLIO
  14.5.4. RECENT DEVELOPMENTS
14.6. B.BRAUN MELSUNGEN AG
  14.6.1. COMPANY OVERVIEW
  14.6.2. REVENUE ANALYSIS
  14.6.3. PRODUCT PORTFOLIO
  14.6.4. RECENT DEVELOPMENTS
14.7. 3-D MATRIX LTD
  14.7.1. COMPANY OVERVIEW
  14.7.2. REVENUE ANALYSIS
  14.7.3. PRODUCT PORTFOLIO
  14.7.4. RECENT DEVELOPMENTS
14.8. RESORBA MEDICAL GMBH
  14.8.1. COMPANY OVERVIEW
  14.8.2. REVENUE ANALYSIS
  14.8.3. PRODUCT PORTFOLIO
  14.8.4. RECENT DEVELOPMENTS
14.9. ANIKA THERAPEUTICS, INC.
  14.9.1. COMPANY OVERVIEW
  14.9.2. REVENUE ANALYSIS
  14.9.3. PRODUCT PORTFOLIO
  14.9.4. RECENT DEVELOPMENTS
14.10. BIOM’UP
  14.10.1. COMPANY OVERVIEW
  14.10.2. REVENUE ANALYSIS
  14.10.3. PRODUCT PORTFOLIO
  14.10.4. RECENT DEVELOPMENTS
14.11. CRYOLIFE, INC.
  14.11.1. COMPANY OVERVIEW
  14.11.2. REVENUE ANALYSIS
  14.11.3. PRODUCT PORTFOLIO
  14.11.4. RECENT DEVELOPMENTS
14.12. EQUIMEDICAL
  14.12.1. COMPANY OVERVIEW
  14.12.2. REVENUE ANALYSIS
  14.12.3. PRODUCT PORTFOLIO
  14.12.4. RECENT DEVELOPMENTS
14.13. HEMOSTASIS, LLC
  14.13.1. COMPANY OVERVIEW
  14.13.2. REVENUE ANALYSIS
  14.13.3. PRODUCT PORTFOLIO
  14.13.4. RECENT DEVELOPMENTS
14.14. MEDTRADE PRODUCTS LIMITED
  14.14.1. COMPANY OVERVIEW
  14.14.2. REVENUE ANALYSIS
  14.14.3. PRODUCT PORTFOLIO
  14.14.4. RECENT DEVELOPMENTS
14.15. STRYKER
  14.15.1. COMPANY OVERVIEW
  14.15.2. REVENUE ANALYSIS
  14.15.3. PRODUCT PORTFOLIO
  14.15.4. RECENT DEVELOPMENTS
14.16. ARCH THERAPEUTICS, INC.
  14.16.1. COMPANY OVERVIEW
  14.16.2. REVENUE ANALYSIS
  14.16.3. PRODUCT PORTFOLIO
  14.16.4. RECENT DEVELOPMENTS
14.17. INTEGRA LIFESCIENCES CORPORATION
  14.17.1. COMPANY OVERVIEW
  14.17.2. REVENUE ANALYSIS
  14.17.3. PRODUCT PORTFOLIO
  14.17.4. RECENT DEVELOPMENTS
14.18. ALTAYLAR MEDICAL
  14.18.1. COMPANY OVERVIEW
  14.18.2. REVENUE ANALYSIS
  14.18.3. PRODUCT PORTFOLIO
  14.18.4. RECENT DEVELOPMENTS
14.19. BIOCER ENTWICKLUNGS-GMBH
  14.19.1. COMPANY OVERVIEW
  14.19.2. REVENUE ANALYSIS
  14.19.3. PRODUCT PORTFOLIO
  14.19.4. RECENT DEVELOPMENTS
14.20. SMI (STARCH MEDICAL)
  14.20.1. COMPANY OVERVIEW
  14.20.2. REVENUE ANALYSIS
  14.20.3. PRODUCT PORTFOLIO
  14.20.4. RECENT DEVELOPMENTS

15. RELATED REPORTS

TABLE LIST

TABLE 1 NORTH AMERICA HEMOSTATSMARKET, BY COUNTRY, 2015 – 2024 (USD MILLION)
TABLE 2 NORTH AMERICA HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 3 NORTH AMERICA HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 4 NORTH AMERICA HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 5 NORTH AMERICA HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 6 U.S. HEMOSTATS MARKET, BY PRODUCT TYPE,2015 – 2024 (USD MILLION)
TABLE 7 U.S. HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 8 U.S.HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 9 U.S. HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 10 CANADA HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 11 CANADA HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 12 CANADA HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 13 CANADA HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 14 MEXICO HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)
TABLE 15 MEXICO HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 16 MEXICO HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 17 MEXICO HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)

Figures

FIGURES LIST

FIGURE 1 NORTH AMERICA IS EXPECTED TO DOMINATE THE MARKET FOR HEMOSTATS AND APAC IS EXPECTED TO BE GROWING WITH THE HIGHEST CAGR
IN THE FORECAST PERIOD TO 2024
FIGURE 2 NORTH AMERICA HEMOSTATS MARKET SNAPSHOT (2017)
FIGURE 3 NORTH AMERICA HEMOSTATS MARKET: BY GEOGRAPHY (2016)
FIGURE 4 NORTH AMERICA HEMOSTATSMARKET:BY COUNTRY (2017)
FIGURE 5 NORTH AMERICA HEMOSTATS MARKET BY COUNTRY (2016 & 2024)
FIGURE 6 NORTH AMERICA HEMOSTATS MARKET BY PRODUCT TYPE (2017 & 2024
FIGURE 7 NORTH AMERICA HEMOSTATS MARKET: COMPANY SHARE 2016 (%)

COMPNIES PROFILES

Baxter, Vascular Solutions, Inc., B.Braun Melsungen, 3-D Matrix, Ltd., Resorba Medical GmbH (an Advanced Medical Solutions Group plc Company), Anika Therapeutics, Inc., Arch Therapeutics Inc., Biom'Up SAS, CryoLife, Inc., Gamma Therapeutics, Inc., Hemostasis, LLC